Markets:

Overview

News

Currencies

International

Treasuries

XBiotech Inc. - Common Stock (NQ:XBIT)

2.340 -0.070 (-2.90%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about XBiotech Inc. - Common Stock

< Previous 1 2 Next >

XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm

January 13, 2025

From The Schall Law Firm

Via Business Wire

XBiotech Pauses Rheumatology program

December 23, 2024

Findings from recently completed Rheumatoid Arthritis Study raise questions

From XBiotech Inc.

Via GlobeNewswire

XBIT Stock Earnings: XBiotech Reported Results for Q2 2024 ↗

August 12, 2024

XBiotech just reported results for the second quarter of 2024.

Via InvestorPlace

What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? ↗

June 18, 2024

XBiotech reveals results from its Phase 1/Phase 2 1-BETTER Study for advanced pancreatic cancer, highlighting the safety and tolerability of Natrunix with the ONIVYDE + 5-Fluorouracil + Leucovorin...

Via Benzinga

XBIT Stock Earnings: XBiotech Reported Results for Q1 2024 ↗

May 13, 2024

XBiotech just reported results for the first quarter of 2024.

Via InvestorPlace

XBIT Stock Earnings: XBiotech Reported Results for Q4 2023 ↗

March 18, 2024

XBiotech just reported results for the fourth quarter of 2023.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Thursday ↗

October 20, 2022

Thursday saw 177 companies set new 52-week lows.

Via Benzinga

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

June 18, 2024

Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy

From XBiotech Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 22, 2024

Via Benzinga

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

January 04, 2024

From XBiotech Inc.

Via GlobeNewswire

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

November 14, 2023

(Phase II Multicenter Study is Proceeding Well with High Anticipation)

From XBiotech Inc.

Via GlobeNewswire

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

September 26, 2023

From XBiotech Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 05, 2023

Via Benzinga

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

August 30, 2023

From XBiotech Inc.

Via GlobeNewswire

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

August 08, 2023

From XBiotech Inc.

Via GlobeNewswire

FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

May 22, 2023

XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment

From XBiotech Inc.

Via GlobeNewswire

Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 17, 2023

Gainers

Via Benzinga

Dow Jumps Over 100 Points; US Housing Starts Rise In April ↗

May 17, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.37% to 33,135.37 while the NASDAQ rose...

Via Benzinga

XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares

May 17, 2023

From XBiotech Inc.

Via GlobeNewswire

XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

April 17, 2023

Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke

From XBiotech Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Monday ↗

November 28, 2022

On Monday, 79 companies reached new 52-week lows.

Via Benzinga

XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer

October 13, 2022

INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in France

From XBiotech Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Thursday ↗

September 22, 2022

On Thursday, 1076 companies hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

August 22, 2022

On Monday, 195 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

July 14, 2022

On Thursday, 550 companies achieved new lows for the year.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

September 20, 2022

On Tuesday, 507 stocks hit new 52-week lows.

Via Benzinga

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗

June 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

September 19, 2022

On Monday, 429 stocks made new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

August 31, 2022

On Wednesday, 238 companies achieved new lows for the year.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

August 01, 2022

On Monday, 92 companies set new 52-week lows.

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.